{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T17:39:45Z","timestamp":1785173985670,"version":"3.55.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Prostate cancer (PC) is one of the most prevalent malignancies in men, with rising incidence and mortality rates globally. Despite advances in therapeutic options such as androgen deprivation therapy and chemotherapy, effective cures, especially for advanced stages of the disease, remain limited. Recent research has highlighted the significant roles of alternative splicing (AS) and noncoding RNAs in tumor progression and drug resistance. This study aims to investigate the role of circIMP3, derived from the IMP3 gene, in prostate cancer development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this study, we employed quantitative PCR, RNA sequencing, and immunoblotting to identify and characterize circIMP3 in prostate cancer tissues and patient blood samples. Functional assays, including cell proliferation and\n                      <jats:italic>in vivo<\/jats:italic>\n                      tumorigenicity assays, were conducted to assess the biological role of circIMP3 in PC cells. RNA immunoprecipitation sequencing (RIP-seq) was used to identify alternative splicing events regulated by circIMP3. Additionally, exosome isolation and uptake assays were performed to explore the paracrine signaling function of circIMP3 within the tumor microenvironment (TME).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified circIMP3, which is significantly upregulated in both prostate cancer tissues and peripheral blood of patients. CircIMP3 contains an internal ribosome entry site (IRES) and encodes a previously uncharacterized 288-amino-acid protein, circIMP3_288aa. Functional assays revealed that circIMP3_288aa promotes cell proliferation\n                      <jats:italic>in vitro<\/jats:italic>\n                      and accelerates tumor growth\n                      <jats:italic>in vivo<\/jats:italic>\n                      . Mechanistically, circIMP3_ 288aa regulates the alternative splicing of FBXW7, leading to impaired c-Myc ubiquitination and stabilization, which enhances oncogenic signaling. RIP-seq analysis identified over 2,000 alternative splicing events regulated by IMP3, with a notable enrichment in pathways related to ubiquitin-mediated proteolysis. Furthermore, circIMP3 is secreted into the TME via exosomes, where it is taken up by recipient cells, contributing to their proliferation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our findings demonstrate that circIMP3 acts as a key regulator of both intracellular alternative splicing and extracellular paracrine signaling within the TME. The ability of circIMP3 to influence FBXW7 splicing and stabilize c-Myc provides a mechanistic basis for its role in promoting oncogenesis in prostate cancer. Clinically, high expression levels of circIMP3 correlate with poorer event-free survival in prostate cancer patients, suggesting its potential as a prognostic biomarker. Additionally, the detection of circIMP3 in peripheral blood positions it as a promising target for liquid biopsy applications in PC diagnosis and monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcell.2025.1722674","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T06:37:42Z","timestamp":1767595062000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A novel protein encoded by circIMP3 promotes prostate cancer progression by regulating alternative splicing and tumor microenvironment"],"prefix":"10.3389","volume":"13","author":[{"given":"Wenren","family":"Zuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizhou","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","article-title":"Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer","volume":"22","author":"Bakht","year":"2025","journal-title":"Nat. Reviews Urol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41571-020-0350-x","article-title":"Roles and mechanisms of alternative splicing in cancer - implications for care","volume":"17","author":"Bonnal","year":"2020","journal-title":"Nat. Reviews Clin. Oncology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e2309902121","DOI":"10.1073\/pnas.2309902121","article-title":"Epidermal growth factor receptor (EGFR) is a target of the tumor-suppressor E3 ligase FBXW7","volume":"121","author":"Boretto","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/andr.13812","article-title":"Prostate cancer and genetic contributions","volume":"13","author":"Chou","year":"2025","journal-title":"Andrology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41568-024-00721-7","article-title":"Circular RNA in cancer","volume":"24","author":"Conn","year":"2024","journal-title":"Nat. Reviews Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate Cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur. Urology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1038\/s41388-024-03099-w","article-title":"N6-methyladenosine modified circPAK2 promotes lymph node metastasis via targeting IGF2BPs\/VEGFA signaling in gastric cancer","volume":"43","author":"Ding","year":"2024","journal-title":"Oncogene"},{"key":"B8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12964-023-01043-1","article-title":"c-MYC mediates the crosstalk between breast cancer cells and tumor microenvironment","volume":"21","author":"Gao","year":"2023","journal-title":"Cell Communication Signaling"},{"key":"B9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.molmed.2023.05.006","article-title":"The ubiquitin-proteasome system in breast cancer","volume":"29","author":"Han","year":"2023","journal-title":"Trends Molecular Medicine"},{"key":"B10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12943-021-01440-5","article-title":"Exosomes in the hypoxic TME: from release, uptake and biofunctions to clinical applications","volume":"21","author":"He","year":"2022","journal-title":"Mol. Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e23771","DOI":"10.1002\/jbt.23771","article-title":"Hsa_circRNA_007630 knockdown delays colon cancer progression by modulation of ferroptosis via miR-506-3p\/AURKA axis","volume":"38","author":"Hu","year":"2024","journal-title":"J. Biochemical Molecular Toxicology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e14735","DOI":"10.1111\/cns.14735","article-title":"CircRNA-associated ceRNA regulatory networks as emerging mechanisms governing the development and biophysiopathology of epilepsy","volume":"30","author":"Kohansal","year":"2024","journal-title":"CNS Neuroscience and Therapeutics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"527","DOI":"10.4111\/icu.20240229","article-title":"Prostate cancer theragnostics biomarkers: an update","volume":"65","author":"Kumar","year":"2024","journal-title":"Investigative Clinical Urology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1007\/s10528-023-10641-0","article-title":"circRNA-CPA4 regulates cell proliferation and apoptosis of non-small cell lung cancer via the miR-1183\/PDPK1 axis","volume":"62","author":"Li","year":"2024","journal-title":"Biochem. Genetics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"133704","DOI":"10.1016\/j.jhazmat.2024.133704","article-title":"ALKBH5 SUMOylation-mediated FBXW7 m6A modification regulates alveolar cells senescence during 1-nitropyrene-induced pulmonary fibrosis","volume":"468","author":"Li","year":"2024","journal-title":"J. Hazardous Materials"},{"key":"B16","doi-asserted-by":"publisher","first-page":"122870","DOI":"10.1016\/j.lfs.2024.122870","article-title":"Research status and potential applications of circRNAs affecting colorectal cancer by regulating ferroptosis","volume":"352","author":"Liang","year":"2024","journal-title":"Life Sciences"},{"key":"B17","doi-asserted-by":"publisher","first-page":"217155","DOI":"10.1016\/j.canlet.2024.217155","article-title":"Advances in and prospects of immunotherapy for prostate cancer","volume":"601","author":"Liu","year":"2024","journal-title":"Cancer Letters"},{"key":"B18","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s12894-024-01634-1","article-title":"MicroRNA in prostate cancer: from biogenesis to applicative potential","volume":"24","author":"Luo","year":"2024","journal-title":"BMC Urology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol. Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1275755","DOI":"10.3389\/fcell.2023.1275755","article-title":"Exosomal non-coding RNAs in glioma progression: insights into tumor microenvironment dynamics and therapeutic implications","volume":"11","author":"Marangon","year":"2023","journal-title":"Front. Cell Developmental Biology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.biochi.2021.11.001","article-title":"A regulatory role of circRNA-miRNA-mRNA network in osteoblast differentiation","volume":"193","author":"Mohanapriya","year":"2022","journal-title":"Biochimie"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2356820","DOI":"10.1080\/15384047.2024.2356820","article-title":"T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer","volume":"25","author":"Palecki","year":"2024","journal-title":"Cancer Biology and Therapy"},{"key":"B23","doi-asserted-by":"publisher","first-page":"bbae466","DOI":"10.1093\/bib\/bbae466","article-title":"Novel systems biology experimental pipeline reveals matairesinol's antimetastatic potential in prostate cancer: an integrated approach of network pharmacology, bioinformatics, and experimental validation","volume":"25","author":"Rajadnya","year":"2024","journal-title":"Briefings Bioinformatics"},{"key":"B24","doi-asserted-by":"publisher","first-page":"100728","DOI":"10.1016\/j.drup.2020.100728","article-title":"The role of alternative splicing in cancer: from oncogenesis to drug resistance","volume":"53","author":"Sciarrillo","year":"2020","journal-title":"Drug Resistance Updates"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/s41417-024-00781-9","article-title":"IGF2BP2-modified circular RNA circCHD7 promotes endometrial cancer progression via stabilizing PDGFRB and activating JAK\/STAT signaling pathway","volume":"31","author":"Shi","year":"2024","journal-title":"Cancer Gene Therapy"},{"key":"B26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13046-022-02276-7","article-title":"A novel protein encoded by circHNRNPU promotes multiple myeloma progression by regulating the bone marrow microenvironment and alternative splicing","volume":"41","author":"Tang","year":"2022","journal-title":"J. Experimental and Clinical Cancer Research CR"},{"key":"B27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41392-024-01734-2","article-title":"Alternative splicing and related RNA binding proteins in human health and disease","volume":"9","author":"Tao","year":"2024","journal-title":"Signal Transduction Targeted Therapy"},{"key":"B28","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur. Urology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1093\/nar\/gkae081","article-title":"RIP-seq reveals RNAs that interact with RNA polymerase and primary sigma factors in bacteria","volume":"52","author":"Va\u0148kov\u00e1 Hausnerov\u00e1","year":"2024","journal-title":"Nucleic Acids Research"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e70016","DOI":"10.1002\/cnr2.70016","article-title":"Prostate cancer: a review of genetics, current biomarkers and personalised treatments","volume":"7","author":"Wilson","year":"2024","journal-title":"Cancer Reports Hob. NJ"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e18733","DOI":"10.7717\/peerj.18733","article-title":"The role of circRNA in breast cancer drug resistance","volume":"12","author":"Yang","year":"2024","journal-title":"PeerJ"},{"key":"B32","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41392-020-00359-5","article-title":"Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression","volume":"5","author":"Yang","year":"2020","journal-title":"Signal Transduction Targeted Therapy"},{"key":"B33","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1186\/s12967-024-05562-4","article-title":"CircRNA as an achilles heel of cancer: characterization, biomarker and therapeutic modalities","volume":"22","author":"Zhang","year":"2024","journal-title":"J. Translational Medicine"}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2025.1722674\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T06:37:43Z","timestamp":1767595063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2025.1722674\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":33,"alternative-id":["10.3389\/fcell.2025.1722674"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2025.1722674","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"article-number":"1722674"}}